CD32 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor, notably of the Src family kinases. CD32 (FcγRII) signaling can be influenced by Src family kinases as they play a role in the initiation of the signaling cascade following receptor activation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is another Src family kinase inhibitor. By inhibiting Src kinases, PP2 impacts the activation of signaling cascades downstream of CD32. This can reduce the phosphorylation of proteins that are essential for propagating the signal from CD32, thus indirectly inhibiting CD32-mediated cellular responses. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphatidylinositol 3-kinase (PI3K). CD32 signaling is partially mediated through the PI3K pathway. By inhibiting PI3K, LY294002 can reduce the downstream signaling events that are necessary for the full activation and function of CD32, thereby modulating its activity indirectly. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. It functions similarly to LY294002 by impairing the PI3K pathway. This inhibition can disrupt the downstream signaling required for effective CD32-mediated responses, indirectly modulating the activity of CD32. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. CD32 signaling can intersect with the mTOR pathway, which is involved in cellular metabolism and survival. Inhibition of mTOR by Rapamycin can alter the cellular context in which CD32 operates, thereby indirectly affecting its signaling capacity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is part of the MAPK/ERK pathway. CD32 can signal through MAPK/ERK pathways, and inhibition of MEK by PD98059 may lead to reduced activation of ERK and subsequent downstream signaling events linked to CD32 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway can be activated downstream of CD32 signaling. Inhibition of p38 MAPK by SB203580 can disrupt the propagation of signals initiated by CD32, thus indirectly modulating its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Since CD32 can engage JNK in its signaling pathways, inhibiting JNK with SP600125 can impair the downstream signaling events that are part of CD32's functional repertoire, leading to an indirect modulation of CD32 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, affecting the MAPK/ERK pathway. By inhibiting MEK, U0126 can disrupt the ERK signaling downstream of CD32, leading to an indirect modulation of CD32 signaling and function. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stattic is known as an inhibitor of STAT3. CD32 signaling can intersect with STAT3-mediated pathways. Inhibition of STAT3 by Stattic can thus indirectly affect the signaling and function of CD32 by altering the STAT3-dependent pathways that CD32 may engage. | ||||||